Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy
A Ribas, JA Glaspy, Y Lee, VB Dissette… - Journal of …, 2004 - journals.lww.com
Abstract MART-1 27–35-peptide-pulsed immature dendritic cells (DCs) resulted in
immunologic and clinical activity in a prior phase 1 trial. A phase 2 cohort expansion was
initiated to further characterize the phenotype and cytokine milieu of the DC vaccines and
their immunologic activity in vitro and to further examine a possible link between clinical
activity and determinant spreading. In an open-label phase 2 trial, 10 7 autologous ex vivo
generated DCs pulsed with the HLA-A* 0201 immunodominant peptide MART-1 27–35 …
immunologic and clinical activity in a prior phase 1 trial. A phase 2 cohort expansion was
initiated to further characterize the phenotype and cytokine milieu of the DC vaccines and
their immunologic activity in vitro and to further examine a possible link between clinical
activity and determinant spreading. In an open-label phase 2 trial, 10 7 autologous ex vivo
generated DCs pulsed with the HLA-A* 0201 immunodominant peptide MART-1 27–35 …